Immupharma PLC European Patients Commence Dosing in Lupuzor (3712A)

TIDMIMM

RNS Number : 3712A

Immupharma PLC

07 June 2016

 
 RNS : FOR IMMEDIATE RELEASE   7 JUNE 2016 
 

ImmuPharma PLC

("ImmuPharma" or the "Company")

FIRST EUROPEAN PATIENTS COMMENCE DOSING IN LUPUZOR'S PIVOTAL PHASE III STUDY

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to provide a further update on the progress of its Phase III clinical trial of Lupuzor(TM), its lead programme for the potential breakthrough compound for Lupus, the life threatening auto immune disease.

ImmuPharma is pleased to confirm that the first European sites opened have now commenced dosing Lupus patients. Recruitment in this pivotal Phase III study for Lupuzor(TM) will occur in up to 45 investigator sites. 10 sites in United States and 35 in Europe.

Further updates on the progression of the Lupuzor(TM) Phase III trial will be announced, as appropriate, as the trial progresses. Progress on the trial can also be seen at: www.ClincialTrials.gov/lupuzor.

Commenting on the event, Tim McCarthy, Chairman, said: "This a further key milestone for ImmuPharma's Lupuzor(TM) trial with now both the US and European sites dosing Lupus patients. We look forward to providing further positive updates on this Lupuzor(TM) Phase III study as it progresses throughout this year and 2017."

Lupuzor Symposium on 8 & 9 June : Key Presenter : Prof. Sylviane Muller

As recently confirmed, a Lupuzor(TM) Symposium is being hosted this week with Prof. Muller, inventor of Lupuzor(TM) presenting on the unique 'Mechanism of Action' of Lupuzor(TM), also known by its chemical name 'Forigerimod' or 'P140'. Prof. Muller will also provide further evidence of the role the P140 molecule can take in the potential treatment of other autoimmune diseases.

For more information or if you would like to attend one of the briefings, please email: [e-mail]. A video of the presentation will be available on the Company's website from Monday 13 June on: www.immupharma.org/events&conference.org.

-Ends-

 
 For further information please 
  contact: 
                                               + 44 (0) 20 
   ImmuPharma plc (www.immupharma.org)          7152 4080 
   Tim McCarthy, Chairman 
   Lisa Baderoon, Head of Investor 
    Relations                                + 44 (0) 7721 
    Twitter: @immupharma                      413496 
   Panmure, Gordon & Co., NOMAD &            [phone] 
    Broker                                         2500 
   Fred Walsh, Duncan Monteith, Corporate 
    Finance 
    Charles Leigh-Pemberton, Corporate 
    Broking 
 

Notes to Editors

ImmuPharma PLC

ImmuPharma is a pharmaceutical development company listed since 2006 on AIM of the London Stock Exchange (LSE:IMM), focusing on developing novel medicines with high sales potential in specialist markets with serious unmet need. ImmuPharma is led by a commercially focused Board and management team with extensive experience.

ImmuPharma announced on 1 March 2016 the successful completion of a GBP8.4 million fund raise, comprising a Placing and Subscription together with confirmation of EIS and VCT qualifying status. Monies raised will principally be used to complete the pivotal Phase III trial of Lupuzor(TM). Following the issue of the New Ordinary Shares ImmuPharma has 121,781,219 ordinary shares of 10 pence each (the "Ordinary Shares") in issue.

Lupuzor(TM)

Lupuzor(TM) (also referred to as Forigerimod, or P140) is ImmuPharma's lead compound and a potential treatment for lupus (or Systemic Lupus Erythematosus), a chronic, potentially life-threatening auto-immune disease. Lupuzor(TM) has a novel mechanism of action aimed at modulating the body's immune system so that it does not attack healthy cells, and avoids causing adverse side effects. It has the potential to halt the progression of the disease in a substantial proportion of patients.

Lupuzor(TM) has been granted Fast Track status by the US FDA and approval to start Phase III under Special Protocol Assessment (SPA). This SPA was subsequently amended due to its strong safety and efficacy profile to allow for a reduced number of patients in the pivotal Phase III trial thereby reducing the projected cost and time of development considerably.

The pivotal Phase III clinical study is entitled "A 52-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus". It is a pivotal study designed to demonstrate the safety and efficacy of IPP-201101 and as a last step prior to the filing of the drug for approval with the US Food & Drug Administration ("FDA") and the European Medicines Agency ("EMA"). For more information please visit: www.ClinicalTrials.gov/lupuzor

Commercial Opportunity

There are an estimated five million people globally suffering from Lupus, with approximately 1.5 million patients in the US, Europe and Japan (Source: Lupus Foundation of America). Current 'standard of care' treatments, including steroids and immunosuppressants, can potentially have either serious side effects for patients or limited effectiveness, with over 60% of patients not adequately treated. GSK's Benlysta is the first Lupus drug approved in over 50 years and paves the path to market for Lupuzor(TM). Based on conservative estimates, and taking into account that Benlysta is priced currently at approximately $35,000 per patient per year, Lupuzor(TM) would be entering a market with the potential for multi-billion dollar sales. For more information on Lupuzor(TM) please visit: www.lupuzor.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

RESUGUGAQUPQGMQ

(END) Dow Jones Newswires

June 07, 2016 02:00 ET (06:00 GMT)